Mesothelioma and Early Lung Cancer Identified by Screening | Surviving Mesothelioma

Mesothelioma and Early Lung Cancer Identified by Screening

26153812_CT Scan

Using computed tomography scans to screen former asbestos workers can detect both early and late-stage lung cancer and late-stage mesothelioma, according to a study in the May Journal of Thoracic Oncology. However, it’s still not clear whether screening for these cancers might improve patients’ prognoses.

Exposure to asbestos fibers is a known risk factor for lung cancer and the cause of mesothelioma. Although asbestos is still not completely banned in the U.S., it was phased out of American industry to a large degree beginning in the 1970s.  However because asbestos-related diseases can take 20 to 40 years to emerge after people have been exposed, former asbestos workers and those exposed to products containing this carcinogen continue to be diagnosed with asbestos caused cancers.

As researchers search for better treatments and even a cure for these diseases, they are also focusing on new diagnostic methods that might identify the cancers earlier. Early diagnosis is particularly crucial with mesothelioma, because many patients survive only one year after they first start to show signs, and symptoms are often difficult to distinguish from those of other lung diseases.

One potential screening method uses low-dose computed tomography (LDCT) to evaluate the lungs and their lining (pleura). LDCT can locate plaques in the lungs, which are a sign of asbestos exposure and have been linked to an increased cancer risk.

Currently, there are no recommendations about using LDCT or any other method to screen people who have been exposed to asbestos, and screening isn’t routinely done. “There are currently no methods for the early detection of mesothelioma available,” says lead author Heidi Roberts, MD, Associate Professor of Radiology at the University of Toronto.  “This is why we are doing the research.”

To determine the effectiveness of LDCT as a screening tool for asbestos-related lung cancers, Dr. Roberts and her colleagues recruited 516 people (most of them men) who had been exposed to asbestos at least 20 years before, or who had known plaques. Participants were given LDCT scans of the chest. Patients who had abnormal scans were given follow-up tests. Those with normal test results were invited to have an annual LDCT scan.

Of the 516 participants, 357 had evidence of plaques. Based on the results of the first scan and annual scans, six of the patients were diagnosed with lung cancers and four were diagnosed with mesothelioma.

Although LDCT was able to detect advanced mesothelioma, as well as early- and late-stage lung cancers, it was not able to diagnose early mesothelioma. The study authors say they need to continue screening patients to help them get a better idea of what early mesothelioma looks like. Also, they say adding biomarkers (substances in the blood that indicate the presence of cancer) to the screening process may provide greater sensitivity to help diagnose those at very high risk for mesothelioma.

Even as techniques are fine-tuned, screening is just one step of a three-tiered effort to combat these cancers, according to Dr. Roberts. “The second step is the parallel development of biomarkers, and the third step is the parallel development of treatment strategies,” she says. “These have to be developed hand-in-hand in order to make this a useful and meaningful tool.”
 
Source:

Roberts HC, Patsios DA, Paul NS, dePerrot M, Teel W, Bayanati H, Shepherd F, Johnston MR. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. Journal of Thoracic Oncology. 2009;5:620-628.

Get your free copy of
“Surviving Mesothelioma” Today!